Rosalba Yobuta

Bodo, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Dual Use of the METSSS Model Predicting Survival After Palliative Radiotherapy: An Exploratory Analysis.

Dual Use of the METSSS Model Predicting Survival After Palliative Radiotherapy: An Exploratory Analysis.

Journal: Cureus

Published: January 04, 2022

Independent External Validation of the METSSS Model Predicting Survival After Palliative Radiotherapy.

Independent External Validation of the METSSS Model Predicting Survival After Palliative Radiotherapy.

Journal: Anticancer research

Published: November 19, 2021

Validation of a Graded Prognostic Model in Patients With Brain Metastases Treated With Whole-brain Radiotherapy Instead of Radiosurgery.

Validation of a Graded Prognostic Model in Patients With Brain Metastases Treated With Whole-brain Radiotherapy Instead of Radiosurgery.

Journal: In vivo (Athens, Greece)

Published: January 15, 2021

Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases.

Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases.

Journal: Anticancer research

Published: January 11, 2021

Expansion of the LabBM Score: Is the LabPS the Best Tool Predicting Survival in Patients With Brain Metastases?

Expansion of the LabBM Score: Is the LabPS the Best Tool Predicting Survival in Patients With Brain Metastases?

Journal: American journal of clinical oncology

Published: December 22, 2020

Palliative Thoracic Radiotherapy for Non-small Cell Lung Cancer: Is There any Impact of Target Volume Size on Survival?

Palliative Thoracic Radiotherapy for Non-small Cell Lung Cancer: Is There any Impact of Target Volume Size on Survival?

Journal: Anticancer research

Published: November 20, 2020

Neurological Death After Radiotherapy for Brain Metastases: Role of the LabBM Score.

Neurological Death After Radiotherapy for Brain Metastases: Role of the LabBM Score.

Journal: Anticancer research

Published: November 15, 2020

Palliative Radiotherapy During the Last Month of Life: Have COVID-19 Recommendations Led to Reduced Utilization?

Palliative Radiotherapy During the Last Month of Life: Have COVID-19 Recommendations Led to Reduced Utilization?

Journal: In vivo (Athens, Greece)

Published: November 14, 2020

LabBM Score and Extracranial Score As New Tools for Predicting Survival in Patients with Brain Metastases Treated with Focal Radiotherapy.

LabBM Score and Extracranial Score As New Tools for Predicting Survival in Patients with Brain Metastases Treated with Focal Radiotherapy.

Journal: Cureus

Published: May 14, 2020

Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer.

Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer.

Journal: Radiation oncology (London, England)

Published: March 11, 2020

Late Brain Oligometastases Diagnosed at Least 36 Months after Cancer Detection are Associated with Favorable Survival Outcome.

Late Brain Oligometastases Diagnosed at Least 36 Months after Cancer Detection are Associated with Favorable Survival Outcome.

Journal: Cureus

Published: February 12, 2020

Provider decision regret-a useful method for analysis of palliative thoracic re-irradiation for lung cancer?

Provider decision regret-a useful method for analysis of palliative thoracic re-irradiation for lung cancer?

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Published: October 17, 2019

Showing 1-12 of 19

Last Updated: 09/26/2026